{"organizations": [], "uuid": "d1db7003ceabd18b0f344a916fa59818f1e8956e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-axsome-therapeutics-says-independe/brief-axsome-therapeutics-says-independent-committee-recommends-continuation-of-depression-trial-idUSASC09XOC", "country": "US", "domain_rank": 408, "title": "Axsome Therapeutics Says Independent Committee Recommends Continuation Of Depression Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.781, "site_type": "news", "published": "2018-04-26T19:40:00.000+03:00", "replies_count": 0, "uuid": "d1db7003ceabd18b0f344a916fa59818f1e8956e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-axsome-therapeutics-says-independe/brief-axsome-therapeutics-says-independent-committee-recommends-continuation-of-depression-trial-idUSASC09XOC", "ord_in_thread": 0, "title": "Axsome Therapeutics Says Independent Committee Recommends Continuation Of Depression Trial", "locations": [], "entities": {"persons": [{"name": "terim", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "axsome therapeutics says independent committee recommends continuation of depression trial", "sentiment": "negative"}, {"name": "axsome therapeutics inc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Axsome Therapeutics Inc:\n* AXSOME THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS OF STRIDE-1 PHASE 3 TRIAL OF AXS-05 IN TREATMENT RESISTANT DEPRESSION\n* AXSOME THERAPEUTICS INC - SECOND INTERIM ANALYSIS ANTICIPATED SECOND HALF OF 2018 FOR EFFICACY\n* AXSOME THERAPEUTICS INC - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TRIAL CONTINUATION\n* AXSOME THERAPEUTICS INC - IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION FROM STUDY AND INDICATED AXS-05 APPEARED SAFE AND WELL-TOLERATED Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T19:40:00.000+03:00", "crawled": "2018-04-27T16:29:12.006+03:00", "highlightTitle": ""}